Search results for "HEMATOPOIETIC STEM"

showing 10 items of 404 documents

Human Haemato-Endothelial Precursors: Cord Blood CD34+ Cells Produce Haemogenic Endothelium

2012

Embryologic and genetic evidence suggest a common origin of haematopoietic and endothelial lineages. In the murine embryo, recent studies indicate the presence of haemogenic endothelium and of a common haemato-endothelial precursor, the haemangioblast. Conversely, so far, little evidence supports the presence of haemogenic endothelium and haemangioblasts in later stages of development. Our studies indicate that human cord blood haematopoietic progenitors (CD34+45+144-), triggered by murine hepatocyte conditioned medium, differentiate into adherent proliferating endothelial precursors (CD144+CD105+CD146+CD31+CD45-) capable of functioning as haemogenic endothelium. These cells, proven to give…

CD31MouseCellular differentiationMESH: HematopoiesisAntigens CD34murine hepatocytesMESH: CadherinsMESH: HepatocytesMice0302 clinical medicineMolecular Cell BiologyHematopoiesiHepatocyteMESH: Animalsendothelial lineageMESH: Antigens CDCells Cultured0303 health sciencesMultidisciplinaryMESH: Culture Media ConditionedStem CellsMedicine (all)QMESH: Infant NewbornRMESH: HemangioblastsAntigens CD45Cell DifferentiationAnimal ModelsCadherinsFetal BloodCell biologyAdult Stem CellsHaematopoiesisPhenotypeconditioned mediummedicine.anatomical_structureCord bloodMedicineHemangioblastCD146Cellular TypesAnimals; Antigens CD; Antigens CD34; Antigens CD45; Cadherins; Cell Adhesion; Cell Differentiation; Cell Shape; Cells Cultured; Culture Media Conditioned; Fetal Blood; Hemangioblasts; Hematopoiesis; Hepatocytes; Humans; Immunophenotyping; Infant Newborn; Mice; Phenotype; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Research ArticleHumanMESH: Cells Culturedendothelial lineage; murine hepatocytes; conditioned mediumMESH: Cell DifferentiationMESH: ImmunophenotypingEndotheliumHemangioblastsScienceMESH: Antigens CD45[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyMESH: PhenotypeImmunophenotypingMESH: Cell Adhesion03 medical and health sciencesModel OrganismsAntigens CDCell AdhesionmedicineAnimalsHumansMESH: Cell ShapeMESH: Fetal BloodProgenitor cellBiologyCell ShapeMESH: Mice030304 developmental biologyBiochemistry Genetics and Molecular Biology (all)MESH: HumansAnimalInfant NewbornMESH: Antigens CD34Hematopoietic Stem CellsHemangioblastHematopoiesisAgricultural and Biological Sciences (all)Culture Media ConditionedImmunologyHepatocytesCadherinLeukocyte Common Antigens030217 neurology & neurosurgeryDevelopmental BiologyPLoS ONE
researchProduct

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted al…

2009

Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo T-cell-depleted allografts with declining donor TCC after day +60. A total of 13 patients received CD8(depl) DLI and 7 patients did not. All but one of the DLI patients converted to complete donor T-cell chimeras, whereas only one non-DLI patient converted spontaneously. DLI induced transient acute GVHD in five and extensive chronic GVHD in two patients. These data suggest the use of CD8(depl) DLI as an effective treatment for mixed TCC, partic…

CD4-Positive T-LymphocytesAntibodies NeoplasmLymphocytemedicine.medical_treatmentHematopoietic stem cell transplantation*Lymphocyte DepletionT-Lymphocyte SubsetsAlemtuzumabddc:616Transplantation Chimera/*immunologyHematopoietic Stem Cell TransplantationAntibodies MonoclonalHematologyMiddle Agedmedicine.anatomical_structureCD52 AntigenLymphocyte TransfusionAlemtuzumabmedicine.drug*GlycoproteinsAdultCD52T cellAntibodies Monoclonal/therapeutic useAntineoplastic AgentsCD4-Positive T-Lymphocytes/*transplantationAntibodies Monoclonal HumanizedLymphocyte DepletionAntigens CDAntigens NeoplasmmedicineAntibodies Neoplasm/therapeutic useHumans*Peripheral Blood Stem Cell TransplantationAgedCell ProliferationGlycoproteinsLymphocyte Transfusion/*methodsTransplantationPeripheral Blood Stem Cell TransplantationTransplantation Chimerabusiness.industryAntineoplastic Agents/therapeutic usemedicine.diseaseTransplantationGraft-versus-host disease*Antigens NeoplasmImmunology*Antigens CDbusinessCD8Bone marrow transplantation
researchProduct

The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into funct…

2000

Abstract Objective . Hyper-IL-6, a fusion protein of interleukin-6 and its specific receptor, together with stem cell factor leads to the proliferation of primitive hematopoietic progenitor cells. Based on these findings, the current study examined whether hyper-IL-6 promotes the growth of precursor cells that can be further differentiated into dendritic cells in the presence of additional cytokines. Methods . Dendritic cell cultures were generated from CD34 + hematopoietic progenitor cells derived either from bone marrow or from peripheral blood. CD34 + cells were cultured in the presence of cytokines for 2 weeks and then used for phenotyping and T-cell stimulation assays. Results . Hyper-…

CD4-Positive T-LymphocytesCancer ResearchRecombinant Fusion ProteinsAntigen presentationBiologyDinoprostoneImmunophenotypingAntigens CDOxytocicsGeneticsCytokine Receptor gp130HumansProgenitor cellAntigen-presenting cellMolecular BiologyCells CulturedInterleukin 3Antigen PresentationStem Cell FactorMembrane GlycoproteinsFollicular dendritic cellsInterleukin-6Tumor Necrosis Factor-alphaGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyHematologyDendritic cellDendritic CellsReceptors InterleukinFlow CytometryHematopoietic Stem CellsHepatitis B Core AntigensReceptors Interleukin-6Recombinant ProteinsCell biologyEndothelial stem cellMyeloid-derived Suppressor CellInterleukin-4Cell DivisionInterleukin-1Experimental hematology
researchProduct

CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib–associated renal carcinoma antigens with ubiquitous or…

2004

AbstractAllogeneic hematopoietic stem cell transplantation can induce considerable tumor remissions in metastatic renal-cell carcinoma (RCC) patients. The precise effector mechanisms mediating these graft-versus-tumor reactions are unknown. We studied RCC-directed CD8+ T-cell responses in blood lymphocytes of healthy individuals matched with established RCC cell lines for HLA-class I. In 21 of 22 allogeneic mixed lymphocyte/tumor-cell cultures (MLTCs), RCC-reactive cytotoxic T-lymphocytes (CTLs) were readily obtained. From MLTCs, 121 CD8+ CTL clones with memory phenotype were isolated. Their anti–RCC reactivity was restricted by multiple classical HLA-Ia molecules, in particular by HLA-A2, …

CD4-Positive T-LymphocytesCytotoxicity ImmunologicGenotypemedicine.medical_treatmentMolecular Sequence DataImmunologyCell SeparationHuman leukocyte antigenHematopoietic stem cell transplantationCross ReactionsBiologyurologic and male genital diseasesBiochemistryEpitheliumCell therapyEpitopesAntigenAntigens NeoplasmmedicineHumansTransplantation HomologousCytotoxic T cellAmino Acid SequenceCarcinoma Renal CellHistocompatibility Antigens Class ICell BiologyHematologyImmunotherapyFlow CytometryHematopoietic Stem CellsTissue DonorsCTL*HealthSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationColonic NeoplasmsImmunologyMitogen-Activated Protein KinasesPeptidesCD8T-Lymphocytes CytotoxicBlood
researchProduct

TLR2 and Dectin-1 Signaling in Mouse Hematopoietic Stem and Progenitor Cells Impacts the Ability of the Antigen Presenting Cells They Produce to Acti…

2020

Microbial recognition by pattern recognition receptors (PRRs) expressed on hematopoietic stem and progenitor cells (HSPCs) not only activates myelopoiesis but also programs the function of the monocytes and macrophages they produce. For instance, changes in HSPC programming modify the ability of macrophages derived from them to produce inflammatory cytokines. While HSPCs exposed to a TLR2 agonist give rise to tolerized macrophages (lower proinflammatory cytokine production), HSPCs treated with Dectin-1 ligands produce trained macrophages (higher proinflammatory cytokine production). However, nothing is known about the impact of HSPC exposure to microbes on the function of antigen presenting…

CD4-Positive T-LymphocytesOvalbuminhematopoietic stem and progenitor cellsCD4 T cellsAntigen-Presenting CellsMice Transgenicantigen presenting cellsLymphocyte Activationinnate immune memoryProinflammatory cytokineLipopeptidesCandida albicansAnimalsTLR2Lectins C-TypeProgenitor cellAntigen-presenting celllcsh:QH301-705.5CD86CD40biologyChemistryCommunicationHistocompatibility Antigens Class IIZymosanGeneral MedicineTh1 CellsHematopoietic Stem CellsAcquired immune systemToll-Like Receptor 2Cell biologyMice Inbred C57BLlcsh:Biology (General)biology.proteinCytokinesTh17 CellsMyelopoiesisCD80Dectin-1Signal TransductionCells
researchProduct

Reconstitution of CD52-Negative CD4 T Cells after Alemtuzumab-Based T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

2008

Abstract The human CD52 molecule is the target of the monoclonal antibody Alemtuzumab, which is used for treating patients with chemo-refractory chronic lymphocytic leukemia as well as for T cell depletion (TCD) in the context of allogeneic hematopoietic stem cell transplantation (HSCT). The molecule is expressed on the surface of lymphocytes, dendritic cells and to a lesser extent on blood-derived monocytes. Previously, investigators have demonstrated that the surface expression of CD52 on T cells is down-regulated after in vitro incubation with Alemtuzumab. By treating purified human CD4 T cells over 4 hours with 10 μg/mL Alemtuzumab in medium supplemented with 10% human AB serum in vitro…

CD52business.industryLymphocyteChronic lymphocytic leukemiaT cellmedicine.medical_treatmentImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryTransplantationmedicine.anatomical_structureImmunologymedicineCytotoxic T cellAlemtuzumabbusinessmedicine.drugBlood
researchProduct

Functionally Altered GPI-Anchor Negative Treg Following Alemtuzumab-Based T-Cell Depletion Are Associated with Acute Gvhd.

2012

Abstract Abstract 3059 Introduction: The monoclonal anti-CD52antibody Alemtuzumab is frequently used for T-cell depletion (TCD) in the context of allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft versus host disease (GVHD). We previously demonstrated the long term persistence of functionally impaired glycosylphosphatidylinositol (GPI)-anchor negative effector T-cells in patients receiving high dose (100mg) Alemtuzumab in combination with a dose reduced conditioning regimen (Fludarabin + Melpahlan) (Meyer, Wagner et al. BMT 2010). Despite of Alemtuzumab-mediated TCD, half of our patients developed acute GVHD. Since regulatory T cells (Treg) play a major role for cont…

CD52business.industrymedicine.medical_treatmentImmunologyFOXP3hemic and immune systemschemical and pharmacologic phenomenaContext (language use)Cell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGraft-versus-host diseaseimmune system diseasesImmunologymedicineAlemtuzumabIL-2 receptorInterleukin-7 receptorbusinessmedicine.drugBlood
researchProduct

Evidence of alloreactive T lymphocytes in fetal liver: implications for fetal hematopoietic stem cell transplantation

2000

The use of hematopoietic stem cells for in utero transplantation to create permanent hematochimerism represents a new concept in fetal therapy, although this approach has provided heterogeneous results. In this paper we have undertaken molecular, phenotypic and functional studies aimed at identifying the presence of fully competent T lymphocytes in samples of fetal livers and cord blood. We found mature VDJ TCR beta chain transcripts in fetal liver cells taken from 7 to 16 weeks of gestation and a similar pattern was detected in cord blood cells sampled from 13.5 to 20.5 weeks of gestation. A Vbeta8 gene sequence comparable to that detected in adult PBMC was found in fetal liver samples at …

CD8 AntigensReceptors Antigen T-Cell alpha-betaT-Lymphocytesmedicine.medical_treatmentT cellGestational AgeHematopoietic stem cell transplantationLiver transplantationGene Rearrangement T-LymphocyteLymphocyte ActivationIn utero transplantationImmunophenotypingAndrologyFetal Tissue TransplantationHumansMedicineRNA MessengerCells CulturedTransplantation ChimeraTransplantationFetusbusiness.industryHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationHematologyFetal BloodFlow CytometryHaematopoiesismedicine.anatomical_structureLiverCord bloodImmunologyStem cellbusinessBone Marrow Transplantation
researchProduct

Advances in haploidentical stem cell transplantation for hematologic malignancies

2016

One of the most important advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the use of alternative donors and cell sources, such as haploidentical transplants (haplo-HSCT) from family donors. Several approaches have been developed to overcome the challenging bidirectional alloreactivity. We discuss these approaches, including ex vivo T-cell-depleted grafts with megadose of CD34(+) cells, not requiring immunosuppression after allogeneic transplantation for graft-versus-host disease (GVHD) prophylaxis, and other strategies using unmanipulated T-cell-replete grafts with intensive immunosuppression or post-transplantation cyclophosphamide to minimize the GVHD. We als…

Cancer ResearchAllogeneic transplantationmedicine.medical_treatmentGraft vs Host DiseaseContext (language use)Hematopoietic stem cell transplantationT-Lymphocytes RegulatoryLymphocyte DepletionDonor Selection03 medical and health sciences0302 clinical medicineReceptors KIRHLA AntigensmedicineHumansCyclophosphamideDonor selectionbusiness.industryHistocompatibility TestingHematopoietic Stem Cell TransplantationImmunosuppressionHematologyAllograftsTransplantationTreatment Outcomesurgical procedures operativeClinical Trials Phase III as TopicOncologyHematologic Neoplasms030220 oncology & carcinogenesisTransplantation HaploidenticalImmunologyStem cellUnrelated DonorsbusinessImmunosuppressive AgentsEx vivo030215 immunologyLeukemia & Lymphoma
researchProduct

Transmission of angioimmunoblastic T-cell lymphoma by bone marrow transplant

2014

Accidental transmission of lymphoma by bone marrow transplant is a rarely reported event [1–5], since candidates are only accepted for hematopoietic stem cell donation after a work-up that routinel...

Cancer ResearchAngioimmunoblastic T-cell lymphomaBone marrow transplantPathologymedicine.medical_specialtybusiness.industryTransmission (medicine)Hematopoietic stem cellHematologymedicine.diseaseLymphomamedicine.anatomical_structureOncologymedicinebusinessLeukemia & Lymphoma
researchProduct